Partial amino acid sequence of purified von Willebrand factor-cleaving protease

Blood

Volumn 98, Issue 6, 2001, Pages 1654-1661

  Gerritsen, Helena E ^a   Robles, Rodolfo ^a   Lämmle, Bernhard ^a   Furlan, Miha ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; CLUSTERIN; POLYMER; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; HYDROPHOBICITY; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN PURIFICATION; PROTEIN STABILITY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0035885962     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1654     Document Type: Article

References (39)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
2. Badimon L, Badimon JJ, Chesbro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost. 1993;70:111-118.
3. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
4. Jansson J-H, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction. Br Heart J. 1991;66:678-682.
5. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb. 1992;12:1063-1070.
6. Qizilbash N, Duffy S, Prentice CRM, Boothby M, Warlow C. von Willebrand factor and risk of ischemic stroke. Neurology. 1997;49:1552-1556.
7. Ruggeri ZM. von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992;86 (suppl 6):11126-11129.
8. Meyer D. von Willebrand factor: a target for inhibition of thrombosis. Nouv Rev Fr Hematol. 1993;35:255-257.
9. Berkowitz SD, Dent J, Roberts J, et al. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest. 1987;79:524-531.
10. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87:6306-6310.
11. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
12. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
13. Tsai H-M, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997;89:1954-1962.
14. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8-13.
15. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435.
16. Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998;57:293-302.
17. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
18. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med. 1998;339:1578-1584.
19. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Baillières Clin Haematol. 2001;14:437-454.
20. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839-2846.
21. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1593.
22. Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol. 1987;24:178-193.
23. Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare. Am J Med Sci. 1998;316:105-119.
24. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999;131:453-462.
25. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
27. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46:185-190.
28. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
29. Keil-Dlouha V, Planchenault T. Potential proteolytic activity of human plasma fibronectin. Proc Natl Acad Sci U S A. 1986;83:5377-5381.
30. Blondeau X, Lambert Vidmar S, Emod I, Turk V, Keil-Dlouha V. Generation of matrix-degrading proteolytic system from fibronectin by cathepsins B, G, H and L. Biol Chem Hoppe Seyler. 1993;374:651-656.
31. Kempfer AC, Farias CE, Silaf MR, Carballo GA, Lazzari MA. Degradation products of partially purified fibronectin induced the loss of large von Willebrand factor multimers at high shear rate [abstract]. Thromb Haemost. 1999;82(suppl):100.
32. 2-macroglobulin-enzyme complexes. J Clin Invest. 1973;52:2175-2184.
33. 2-macroglobulin-enzyme complexes toward human factor VIII/von Willebrand factor Biochemistry. 1983;22:1437-1444.
34. 2-macroglobulin half-molecules with plasmin as a probe of protease binding site structure. Biochemistry. 1983;22:4933-4940.
35. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95-98.
36. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem. 1999;274:6875-6881.
37. Pankhurst GJ, Bennett CA, Easterbrook-Smith SB. Characterization of the heparin-binding properties of human clusterin. Biochemistry. 1998;37:4823-4830.
38. Hochgrebe T, Pankhurst GJ, Wilce J, Easterbrook-Smith SB. pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. Biochemistry. 2000;39:1411-1419.
39. Fujikawa K, Suzuki H, McMullen B, and Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666.